Health care stocks were higher Monday afternoon, with the NYSE Health Care Index up 0.4% and the Health Care Select Sector SPDR Fund (XLV) adding 0.6%
The iShares Biotechnology ETF (IBB) fell 1.1%.
In corporate news, AbbVie (ABBV) said it struck a licensing deal with Danish biotechnology company, Gubra, to develop a potential candidate for obesity treatment. AbbVie shares rose 1%.
Pliant Therapeutics (PLRX) shares fell 52% after it said it has ended its Beacon-IPF phase 2b trial of bexotegrast in idiopathic pulmonary fibrosis after an independent review found an imbalance in IPF-related adverse events between treatment and placebo groups.
TG Therapeutics' (TGTX) shares jumped past 18% after it reported Q4 net income of $0.15 per diluted share, swinging from a loss of $0.10 a year earlier.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.